Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity

PHASE4CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

July 1, 2024

Conditions
Type 2 Diabetes MellitusGlucotoxicity
Interventions
DRUG

Sitagliptin and Gliclazide

Participants in this arm will receive sitagliptin phosphate 100 mg once daily combined with gliclazide sustained-release tablets 30-120 mg once daily for 12 weeks

DRUG

Metformin

Participants in this arm will receive metformin 500 mg to 2000 mg per day, divided into two doses, for 12 weeks

Trial Locations (1)

510120

Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Nanfang Hospital, Southern Medical University

OTHER

lead

Zhibin Xu

OTHER

NCT06613750 - Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity | Biotech Hunter | Biotech Hunter